03:40:33 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



InMed Pharmaceuticals Inc
Symbol IN
Shares Issued 57,809,524
Close 2015-09-02 C$ 0.205
Market Cap C$ 11,850,952
Recent Sedar Documents

InMed Pharmaceuticals appoints Brennan CEO

2015-09-03 06:33 ET - News Release

Mr. Craig Schneider reports

INMED APPOINTS PAUL BRENNAN AS PRESIDENT & CHIEF EXECUTIVE OFFICER

Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed Pharmaceuticals Inc. as president and chief executive officer, effective Sept. 14, 2015. Mr. Brennan succeeds Craig Schneider, who will remain on the board of directors.

Craig Schneider, director, stated: "We are extremely pleased that at this critical stage in the company's development, Mr. Brennan will be taking the helm of InMed and leading the company through to its next clinical trials, financings and infrastructure buildout. Paul has extensive merger and acquisition, general management, financial, corporate, and drug development expertise. We are fortunate to be under the leadership of an executive with broad global pharmaceutical development and commercialization experience with a proven track record of successfully bringing life science products to market on a global scale. We are pleased to bring his experience to bear on InMed's operations as we make progress toward delivering meaningful therapies to underserved markets."

Mr. Brennan was previously senior vice-president of business development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals -- Nasdaq). Previously he has held a number of senior management and consulting positions at biotech companies based in the United States and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was senior vice-president, business development, at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915-million. Mr. Brennan was also employed at AnorMED where he held a number of roles, including acting president during which time he was involved in the sale of AnorMED to Genzyme for $580-million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.

"I am excited for this opportunity and am excited to lead our talented and dedicated team. InMed's corporate strategy, strong pipeline and innovative development programs, provides a solid basis for long-term value. I am passionate about our prospects, and look forward to working for the benefit of patients, physicians and shareholders as we advance our products through the clinic and into the market to deliver innovative and efficacious products."

Mr. Brennan earned his BSc in life sciences and his MSc in physiology from Queen's University, in Kingston, Ont.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.